Promising ETA selective antagonist after ABT-627/ABT-546.

被引：0
|
作者：
Jai, HS [1 ]
Winn, M [1 ]
Chiou, WJ [1 ]
Nguyen, B [1 ]
Marsh, KC [1 ]
von Geldern, TW [1 ]
机构：
[1] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2001年 / 221卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
57-MEDI
引用
收藏
页码：U10 / U10
页数：1
相关论文
共 46 条
  • [41] Structure activity studies leading to the identification of ABT-980(Fiduxosin):: A novel selective α1A/α1D antagonist for the symptomatic treatment of benign prostatic hyperplasia (BPH).
    Drizin, I
    Altenbach, RJ
    Basha, F
    Carroll, W
    Sippy, K
    Tietje, K
    Hancock, A
    Buckner, S
    Meyer, M
    Kerwin, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 220 : U588 - U589
  • [42] Selective brain region activation by histamine H3 receptor antagonist/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression
    Munari, L.
    Provensi, G.
    Passani, M. B.
    Blandina, P.
    NEUROPHARMACOLOGY, 2013, 70 : 131 - 140
  • [43] Expression of Bcl-2 pro-survival family proteins predicts pharmacological responses to ABT-199, a novel and selective Bcl-2 antagonist, in multiple myeloma models
    Sampath, Deepak
    Punnoose, Elizabeth
    Beghaert, Erwin
    Belmont, Lisa
    Peale, Franklin
    Nguyen Tan
    Chen, Jun
    Darbonne, Walter
    Yue, Peng
    Oeh, Jason
    Lee, Leslie
    Fairbrother, Wayne J.
    Souers, Andrew J.
    Elmore, Steven W.
    Leverson, Joel D.
    CANCER RESEARCH, 2013, 73 (08)
  • [44] Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bc1-2 Antagonist, in Multiple Myeloma Models
    Sampath, Deepak
    Punnoose, Elizabeth
    Boghaert, Erwin R.
    Belmont, Lisa
    Chen, Jun
    Peale, Franklin
    Nguyen Tan
    Darbonne, Walter
    Yue, Peng
    Oeh, Jason
    Lee, Leslie
    Fairbrother, Wayne J.
    Souers, Andrew J.
    Elmore, Steve W.
    Leverson, Joel D.
    BLOOD, 2012, 120 (21)
  • [45] Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]:: I.: Potent and selective histamine H3 receptor antagonist with drug-like properties
    Esbenshade, TA
    Fox, GB
    Krueger, KM
    Miller, TR
    Kang, CH
    Denny, LI
    Witte, DG
    Yao, BB
    Pan, LP
    Wetter, J
    Marsh, K
    Bennani, YL
    Cowart, MD
    Sullivan, JP
    Hancock, AA
    Esbenshade, T
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (01): : 165 - 175
  • [46] Pharmacological properties of ABT-239[4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]:: II.: Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist
    Fox, GB
    Esbenshade, TA
    Pan, JB
    Radek, RJ
    Krueger, KM
    Yao, BB
    Browman, KE
    Buckley, MJ
    Ballard, ME
    Komater, VA
    Miner, H
    Zhang, M
    Faghih, R
    Rueter, LE
    Bitner, RS
    Drescher, KU
    Wetter, J
    Marsh, K
    Lemaire, M
    Porsolt, RD
    Bennani, YL
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (01): : 176 - 190
12345